Skip to main content

Government News



  • MoU between India and Suriname in the field of Medical Products Regulation

    The Union Cabinet, chaired by the Prime Minister Shri Narendra Modi, was apprised of a Memorandum of Understanding (MoU) signed on 4th June, 2023 between the Central Drugs Standard Control Organization (CDSCO), Ministry of Health and Family Welfare, Government of the Republic of India and Ministry of Health, Government of the Republic of Suriname on cooperation in the field of Medical Product Regulation. This was signed during the visit of the President of India to Suriname.

  • Government to open 25000 Jan Aushadhi Kendras

    Government to open 25000 Jan Aushadhi Kendras to make medicines available at affordable prices. Prime Minister Shri Narendra Modi during his Independence Day speech at Red Fort said that the government has plans to increase the number of 'Jan Aushadhi Kendras' from 10,000 to 25,000.

  • CDSCO issued show-cause notices to various epharmacy companies

    Central Drugs Standard Control Organization (CDSCO) has issued show- cause notices to various firms engaged in online/internet sale of Drugs on 8th & 9th February 2023.

    The firms have mostly responded by stating that they are only providing an online platform for facilitating the sale of pharmaceutical products to customers and the platform operates solely as intermediaries, connecting the users and the licensed pharmacies.

  • Parliament passes the Anusandhan National Research Foundation (NRF) Bill, 2023

    Union Minister for Science & Technology Dr Jitendra Singh said here today that "Anusandhan National Research Foundation" will define the stature of India at 2047. Replying to the discussion on "Anusandhan National Research Foundation (NRF) Bill, 2023" in the Rajya Sabha, Dr Jitendra Singh said, the Anusandhan Act will pave the way for India to join the select league of developed nations.

  • Recent measures by CDSCO to remove hazardous products from pharma market

    CDSCO has taken serious action against companies which were alerted by WHO for suspicious activities and involved in production of hazardous products in the market.

    WHO has issued alerts in three cases of syrup products exported from India. Subsequent to the reports, Central Drugs Standard Control Organization (CDSCO) in coordination with State Drug Controllers carried out joint investigations.

  • Indian government helping hands in rare disease treatment

    The Indian government has taken a dominant step towards treatment of patients suffering from rare diseases. So far in this fiscal year, the government has allocated Rs. 92.84 crore for treatment of rare diseases.

    As per the data available with Indian Council of Medical Research (ICMR), 9,675 patients have been enrolled since November, 2019 on the portal of National Registry for Rare and Other Inherited Disorders (NRROID) out of which 4,408 patients are from centrally governed Hospitals.

  • Biotech StartUps are crucial to Indias future economy

    Union Minister of State (Independent Charge) for Science and Technology, MoS PMO, Department of Atomic Energy and Department of Space and MoS Personnel, Public Grievances and Pensions, Dr Jitendra Singh has said that the Biotech StartUps are crucial to India’s future economy.

  • PCI opposes Jharkhand governments announcement on granting permission to open pharmacies by unqualified people

    The Pharmacy Council of India (PCI) has urged the Jharkhand government to recall its decision of granting permission for opening pharmacies in rural areas without registered pharmacists.

  • CDSCO to publish daily analysis reports of cough syrup for export

    CDSCO to update on a daily basis about batches of cough syrup samples received at each of the central or state drug laboratories. This is to enable work distribution amongst the lab and for release of test reports in a time bound manner by these laboratories.

    There is an ongoing global threat posed by toxic cough syrups, the World Health Organization (WHO) told Reuters. The WHO issued safety alerts last year for Indian-made products found in Gambia and Uzbekistan, and this year in Micronesia and the Marshall Islands.

  • Indian Drugs Controller approves first indigenously developed animal-derived tissue engineering scaffold for healing skin wounds with minimum scarring

    The first indigenously developed tissue engineering scaffold from mammalian organs, an animal-derived Class D Biomedical Device that can rapidly heal skin wounds at low-cost with minimum scarring, has received approval from the Indian Drugs Controller.

Subscribe to Government News